Genetically Modified Cell-based Therapy Naming Scheme

Recently there have been revisions in naming genetically modified cell-based therapies. In the past, these types of therapies were named as cellular therapies using the infix "-gen-" for cells that were transduced with a gene.

The Office of Cellular, Tissue and Gene Therapies (OCTGT) group of the FDA, the USAN Council and the INN agreed to use a 2-word naming scheme for genetically modified cell-based therapies. The first word is to be the same as the gene therapy first word for the gene. The second word suffix is "-cel" and a cell type infix is included before the "-cel" ending.

As shown below, both words will only contain one infix.

First Word: Corresponds to the Gene Component

Prefix: Random to contribute euphonious and distinctive name.

Infix: To identify the gene using existing infixes for biological products or using a similar infix for the protein for which the gene codes:

-ald- adrenoleukodystrophy (ALD) protein

-beglo- ?A-t87Q-globin

-bermin- vascular endothelial growth factor

-cabta- cell expressed antibody and T cell activation

-cima- cytosine deaminase

-ermin- growth factor

-etid- eczema-throbocytopenia-immunodeficiency syndrome

-far- interferon

URL: https://www.ama-assn.org/about/united-states-adopted-names/genetically-modified-cell-based-therapy-naming-scheme
Copyright 1995 - 2021 American Medical Association. All rights reserved.
-fermin- fibroblast growth factor
-kin- interleukins
-lim- immunomodulator
-lip- human lipoprotein lipase
-mul- multiple genes
-naco- coagulation factor IX
-nad- NADH dehydrogenase
-nermin- tumor necrosis factor (TNF)
-octoco- coagulation factor VIII
-pap- human papilloma virus
-papkino- human papilloma virus and IL-2
-permin- hepatocyte growth factor
-repi- REP-1 gene
-reti- retinal pigment
-semn- SMN
-stim- colony stimulating factor
-tima- thymidine kinase
-tusu- tumor suppression

Suffix:  - (a vowel) gene: e.g., -(o)gene

**Second Word: Corresponds to the Vector and Cell Component**
**Prefix:** Random to contribute euphonious and distinctive name.

URL: https://www.ama-assn.org/about/united-states-adopted-names/genetically-modified-cell-based-therapy-naming-scheme
Copyright 1995 - 2021 American Medical Association. All rights reserved.
**Infix:** Cell type; reference USAN/INN infix for cell type:

- **ada-** adenosine deaminase
- **co(n)-** chondrocytes
- **den-** dendritic cells
- **end(o)-** endothelial cells
- **ep(a)-** hepatocytes
- **fi(b)-** fibroblasts
- **isle-** islet cells
- **ker(a)-** keratinocytes
- **leu-** lymphocytes/monocytes/ APC (white cells)
- **mestro-** mesenchymal stromal cells
- **mio(b)-** myoblasts
- **ova-** ovary cells
- **pla(c)-** placental cells
- **ren-** renal tubular cells
- **ret-** retinal cells
- **tem-** stem cells
- **tesi-** testis cells
- **tu-** tumor cells
- **ubi-** umbilical cord cells (formerly -cor-)
- **ur-** urothelial cells

**URL:** https://www.ama-assn.org/about/united-states-adopted-names/genetically-modified-cell-based-therapy-naming-scheme

Copyright 1995 - 2021 American Medical Association. All rights reserved.
Suffix: -cel